Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries
Launched by BRISTOL-MYERS SQUIBB · Jan 13, 2015
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
Observational Model, Other- This is a non-interventional, cross-sectional study in the EEA involving representative samples of HCPs who treat patients with Eliquis, as well as patients treated with Eliquis. This study will be facilitated via web-based surveys used to evaluate the effectiveness of the Eliquis Prescribe Guide and Patient Alert Card as risk management tools.
Enrollment: 384 Health Care Professions (HCPs) and 192 Patients
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults (VTEt)
Prevention of VTE in adult pati...
Gender
ALL
Eligibility criteria
- • For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
- Inclusion Criteria:
- • HCP must have been involved in the treatment of at least one patient with Eliquis for any approved indication
- • Patients must have taken Eliquis for any approved indication
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Princeton, New Jersey, United States
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials